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Abstract
Background: Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine and mediator of
acute and chronic inflammatory diseases. MIF is overexpressed in various tumours and has been suggested
as a molecular link between chronic inflammation and cancer. MIF overexpression is observed in breast
cancer but its causal role in the development of this tumour entity is unclear.
Methods: MIF levels in breast cancer cell lines were determined by ELISA and Western blot. CD74 was
measured by Western blot, fluorescence microscopy and flow cytometry. Cell proliferation was studied
by BrdU incorporation, cell adhesion by Matrigel adhesion assay, and cell invasion by migration assay
through Matrigel-coated filters using the Transwell system. MIF expression in primary human breast
cancers was measured by tissue microarray and a semi-quantitative immunoreactivity score (IRS) and
comparison with histopathological parameters and patient outcome data.
Results: MIF was abundantly expressed in the non-invasive breast cancer cell lines MDA-MB-468 and ZR-
75-1, but not in invasive MDA-MB-231 cells, which in turn expressed higher levels of the MIF-receptor
CD74. Stimulation with exogenous MIF led to a dramatic upregulation of MIF secretion (50-fold) in MDA-
MB-231 cells. Autocrine MIF promoted tumour cell proliferation, as indicated by blockade of MIF or CD74
in MDA-MB-231 and MDA-MB-468, and MDA-MB-231 invasiveness was enhanced by exogenous MIF. We
correlated the expression of MIF with histopathological parameters and patient outcome data, using a
tissue microarray of 175 primary invasive breast cancers and 35 normal control tissues. MIF was
upregulated in breast cancer versus normal tissue (median IRS = 8 versus 6). MIF expression showed
positive correlations with progesterone (p = 0.006) and estrogen (p = 0.028) receptor expression,
markers of a favourable prognosis and a negative correlation to tumour size (p = 0.007). In line with these
data, disease-specific overall (OS) as well as recurrence-free (RFS) survival was significantly improved in
breast cancer patients with abundant cytosolic MIF expression compared to MIF low expressers (5-year
OS = 67% versus 50%, p = 0.0019; 5-year RFS = 52% versus 36%, p = 0.0327).
Conclusion: We conclude that intracellular expression of MIF in breast cancer cells is beneficial, whereas
extracellular MIF may play a pro-oncogenic role in promoting breast cancer cell-stroma interactions.
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Macrophage migration inhibitory factor (MIF) is a pleio-
tropic cytokine and upstream regulator of the host immu-
nity that promotes cellular inflammatory responses such
as mitogen-activated protein kinase (MAPK) signalling,
tumour necrosis factor-α (TNF-α) secretion or cyclooxyge-
nase-2 (COX-2) activity. Owing to its inflammatory activ-
ities, MIF is a pivotal mediator of acute and chronic
inflammatory diseases including septic shock, rheuma-
toid arthritis, and atherosclerosis [1-4]. MIF is not only
secreted by immune cells, but also by parenchymal and
tumour cells upon inflammatory and stress stimulation
[1]. Sharing an architectural 3D similarity with the ather-
ogenic and angiogenic chemokine interleukin-8 (IL-8)/
CXCL8, MIF was found to function as a non-cognate lig-
and of CXCR2 and as chemokine-like function (CLF)
chemokine. Inflammatory leukocyte recruitment is
dependent on MIF-CXCR2 and MIF-CXCR4 interactions
[5]. As observed for CLF chemokines, MIF action is not
limited to the extracellular space, but also occurs intracel-
lularly. MIF is found in the cytosol of various cell types,
where it contributes to cell survival, cell cycle and home-
ostasis control. Intracellular MIF activities are linked to c-
Jun activation domain binding protein-1 (JAB1), the
tumour suppressor protein p53, and the thiolprotein oxi-
doreductase (TPOR) activity of MIF [1,6-8].
MIF has been implicated in cancerogenesis already as
early as in 1999, when Mitchell and colleagues found that
it mimics the action of oncogenic RAS protein by inducing
sustained ERK1/2 signalling [9]. Meanwhile, it has been
appreciated that MIF constitutes an important link
between chronic inflammation and cancer. Of note, MIF
levels are markedly elevated in numerous tumour entities
such as prostate tumours, breast cancer, or colon carcino-
mas [10-12]. Recombinant MIF (rMIF) promotes cell pro-
liferation and migration and blockade of MIF by
antibodies or gene deletion leads to reduced proliferation
and inhibition of tumour growth and angiogenesis [13-
18]. Pro-tumourigenic activities of MIF involve the MIF
receptor CD74 and stimulation of the phosphoinositide-
3-kinase (PI3K)/AKT/SRC signal transduction cascade
[9,19-21]. Moreover, MIF inhibits p53-dependent gene
expression and suppresses apoptosis. Secretion of MIF by
tumour cells has been proposed to enhance tumour cell
proliferation by autocrine amplification as known for
other growth factors expressed by cancer cells
[6,18,22,23]. CD74 is expressed on various cancer cells,
i.e. prostate cancer cells, B lymphomas, or gastric carcino-
mas [24-26], but its expression in breast cancer has not
been studied. Of note, binding of MIF to CD74 leads to
the recruitment of the hyaluronate receptor CD44 and
CD74/CD44 complexes have been implicated in pro-
tumourigenic MIF signalling processes [27,28]. Although
its precise role has remained unclear, CD44 has been
amply associated with breast cancer pathogenesis [29,30].
MIF is overexpressed in various breast cancer cell lines and
human breast cancer tissue but its functional role in the
pathogenesis of this tumour entity is poorly understood
[12,21,31]. Given that intracellular MIF has been reported
to have a beneficial role in improving cell homeostasis
and that secreted and extracellular MIF has various pro-
tumourigenic and pro-inflammatory effects, it is conceiv-
able that the clinicopathological role of MIF in breast can-
cer is complex and may vary with tumour stage and type.
Hagemann et al. investigated MIF induction in breast
tumour-stroma interactions. MIF was identified as a major
gene product upregulated in breast cancer cells upon coc-
ulture with macrophages. TNFα-triggered tumour cell-
derived MIF led to increased macrophage metalloprotein-
ase production rates and facilitated tumour cell invasion
[32].
To clarify the causal involvement of MIF in breast cancer,
we investigated the role of MIF and its receptor CD74 in
cytokine production, proliferation, and invasion of inva-
sive versus non-invasive breast cancer cells. Moreover, we
undertook a comprehensive study correlating MIF expres-
sion levels in 175 breast cancer specimens with clinico-
pathological parameters and patient outcome data
including overall (OS) and recurrence-free survival (RFS).
Methods
Breast cancer tissue microarray (TMA)
A TMA was constructed as described previously [33] and
contained 289 non-selected formalin-fixed, paraffin-
embedded primary breast cancers (stage I-IIIC) together
with matched normal breast tissue. All patients gave
informed consent for retention and analysis of their tissue
for research purposes and the study was approved by the
Ethical Committee of the University of Regensburg. An
experienced surgical pathologist (A.H.) evaluated H&E-
stained slides of all specimens before construction of the
TMA to identify representative tumour areas and to re-
evaluate tumour grading. Clinical follow-up, provided by
the Central Tumor Registry Regensburg, Germany, was
available for all breast cancer patients with a median fol-
low-up period of 79 months (0–148 months). Clinico-
pathologic parameters of breast cancer cases included in
the TMA are summarized in a supplementary table (see
Additional File 1).
Cells and reagents
Cell culture reagents were purchased from Invitrogen.
Neutralising anti-CD74 monoclonal antibodies (mAbs)
(sc-5438) were from Santa Cruz and FITC-labelled anti-
CD74 was from Biomedia. The anti-MIF mAb NIH/III.D9
was from the Bucala lab (New Haven, USA) and controlPage 2 of 18
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mAb was from MP Biomedicals, sheep anti-mouse (Fab')2
from GE Healthcare and FITC-labelled anti-mouse anti-
body from Dianova. Polyclonal anti-MIF antibody
(Ka565) and rMIF were generated as described [5].
The normal breast epithelial line MCF-12A, non-invasive
breast cancer cell lines MDA-MB-468 (infiltrating adeno-
carcinoma) and ZR-75-1 (infiltrating ductal carcinoma),
and highly invasive MDA-MB-231 cells (invasive ductal
carcinoma) were cultured as described [21].
Cell lysis and Western blotting analysis
Cell lysates for Western blotting were prepared from
100.000 cells and subjected to NuPAGE® electrophoresis/
Western blotting as described [21]. MIF and CD74 were
detected by anti-CD74 (sc-5438; Santa Cruz) and anti-
MIF (Ka565) primary antibodies, respectively; anti-actin
(C4; 1:500 dilution) was used for standardisation. Fol-
lowing treatment with HRP-conjugated secondary Ab,
bands were quantified by ECL chemiluminescence as
described [21]. Quantifications of blots are representative
of 3–5 independent experiments.
Stimulations with rMIF and MIF ELISA
Cells were incubated at 100,000 cells per well in medium
containing 10% FCS for 24 h at 37°C. Medium was
adjusted to low serum (0.5% FCS) and cells cultured for
48 h. 150 ng/ml of rMIF were added to cells 10 min to 48
h before the end of the incubation. Control incubations
were performed for each time interval. Supernatants were
analysed for MIF by commercial human MIF ELISA (R&D
Systems). For each time interval, 3–6 independent experi-
ments were performed and each sample was analysed by
triplicate ELISA measurements.
Fluorescence microscopy
Living cells were seeded on cover slips in 6-well plates.
Washed cells were incubated in PBS with FITC-labelled
anti-CD74 Ab for 1 h. Control cells were treated with an
irrelevant FITC-labelled antibody. After fixation, cells
were analysed by fluorescence microscopy and 10 pictures
evaluated for each sample.
Proliferation assay
8,000 cells were plated and proliferation measured over
24–72 h followed by a 6 h incubation with BrdU using a
commercial BrdU proliferation kit from Roche Diagnos-
tics. Antibodies for neutralisation experiments and iso-
type control IgG (58 μg/ml), and/or rMIF at different
concentrations (0, 10, 50, and 150 ng/ml) were added at
the beginning of the incubation period.
Matrigel invasion assay
Matrigel invasion assay was conducted in 24-well plates
applying the Transwell device containing microporous 8
μm membranes (Corning, USA). Membranes were coated
with Matrigel (500 ng/ml) and MDA-MB-231 cells seeded
in the upper chamber containing basal medium with
0.5% BSA. rMIF was added to the lower chamber at final
concentrations between 0 and 100 ng/ml. 10% FCS served
as positive chemoattractant control. Migration/invasion
was followed for 72 h. Transwell inserts were transferred
to a new plate and cells adhering to the lower surface were
stained with 8 mM calcein (Calbiochem). The total
number of invading cells was acquired in six representa-
tive fields using fluorescence microscopy (10 × magnifica-
tion).
Real-time PCR
Total RNA processing and real-time PCR were performed
as described [34]. PCR primer sequences: MIF-F312
(5'AGAACCGCTCCTACAGCAAG 3') and MIF-R432 (5'
GAGTTGTTCCAGCCCACATT 3'). Intensity was normal-
ised to GAPDH. PCR conditions were: 95°C for 5 min; 40
cycles of 95°C for 20 s, 61°C for 61 s, and 72°C for 12 s;
60 s at 72°C. Relative quantification of gene expression
was performed using the comparative CT (ΔΔ CT)
method.
Immunohistochemistry
Three μm micrometer sections were prepared and immu-
nohistochemically stained as described elsewhere [34].
Tissue sections were stained with an anti-human MIF anti-
body (MAB289, R&D Systems) at a 1:400 dilution.
Statistical analyses
In vitro assays: Results are expressed as means ± SD.
Graphs were created with Origin Pro 7.0 (Origin Corp.)
and data analysed with Student's t-test.
TMA: MIF protein expression was quantified using the
immunoreactive score of Remmele and Stegner which
consists of the mathematical product of quantity (score 0–
4) and intensity (score 1–3) of protein staining [35]. Sta-
tistical analyses were performed using SPSS version 14.0
(SPSS). Two-sided Tarone-Ware tests/Fisher's exact tests
were performed to correlate RFS and OS with MIF expres-
sion and clinicopathological parameters. Multivariate
proportional hazard Cox regression was performed to test
for independent prognostic relevance. The limit for
reverse selection procedures was p = 0.2. The proportion-
ality assumption for all variables was assessed with log-
negative-log survival distribution functions.
Differences were considered significant at p values < 0.05.Page 3 of 18
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Differential expression of MIF and CD74 in invasive versus 
non-invasive breast cancer cells
We first applied quantitative PCR (Figure 1a) and Western
blotting (Figure 1b–c) to study the mRNA and protein
expression levels of MIF, respectively, in various invasive
and non-invasive ductal breast cancer cell lines in com-
parison to normal epithelial cells. Non-invasive MDA-
MB-468 and ZR-75-1 cells showed an upregulation of MIF
compared to benign epithelial MCF-12A cells, both at the
mRNA and protein level, confirming earlier observations
[21]. Surprisingly, invasive MDA-MB-231 breast cancer
cells exhibited significantly lower MIF mRNA and protein
levels when compared with the non-invasive cells or MCF-
12A. Thus, MIF de novo synthesis and intracellular protein
storage differ between normal epithelial and breast cancer
cells and highly invasive cells produce low concentrations
of this cytokine.
Next, we measured expression of the MIF receptor CD74
by Western blotting, immunocytochemistry (IHC), and
flow cytometry (Figure 2). Generally, CD74 expression
was not very prominent in the cells tested. Western blot-
ting and IHC analysis showed marked expression of CD74
in MDA-MB-231, but expression was weak to absent in
MDA-MB468 and MCF-12A, as judged by these methods,
respectively. IHC indicated that CD74 expression in
MDA-MB-231 was mostly intracellular, an observation
that was in line with previous knowledge on the cellular
distribution of CD74/Ii. Flow cytometry analysis con-
firmed that in MDA-MB-231 cells, some portion of CD74
was localised on the cell surface (Figure 2c). Interestingly,
this method also revealed surface expression of CD74 on
MDA-MB-468 and MCF-12A cells, which was comparable
to that on MDA-MB-231 cells. Overall, invasive MDA-MB-
231 cells exhibited the highest levels of CD74, which were
mostly intracellular. Thus, CD74 appears to be primarily
expressed in invasive breast cancer cells, indicating that
such tumour cells may be prone to stimulation with MIF.
MIF secretion by breast cancer cells is dramatically 
upregulated by exogenous MIF
Upon inflammatory stimulation, tumour cells secrete
growth factors and cytokines, which amplify neoplastic
tumour cell transformation and participate in tumour-
stroma interactions and activation of tumour-associated
macrophages (TAMs). MIF is produced and secreted by
both monocytes/macrophages and tumour cells and has
pro-tumourigenic activities in vitro. To begin to study
potential amplifying effects of exogenous MIF, i.e. MIF
released in the tumour microenvironment by TAMs or
breast cancer cells themselves, we examined the secretion
of MIF in unstimulated breast cancer cells and in those
exposed to exogenous recombinant MIF (rMIF). First,
spontaneously secreted MIF levels were measured in
unstimulated MCF-12A, MDA-MB-468, and MDA-MB-
231 cells by ELISA. In both tumour cell lines, accumulated
MIF concentrations in the supernatants reached apprecia-
ble concentrations (Figure 3a), whereas no constitutive
MIF release was observed in MCF-12A. The MIF secretion
rate in MDA-MB-468 was 4–6-fold higher than in MDA-
MB-231, reaching >35 ng/ml after 48 h. Thus, in cycling
breast cancer cells, MIF production and secretion rates
exceeded re-endocytosis and degradation.
We next studied the effect of rMIF on the secretion rate of
endogenous MIF. Notably, treatment with 150 ng/ml
rMIF not only stimulated endogenous MIF secretion con-
stituting an autocrine loop, but led to a remarkable upreg-
ulation of MIF secretion in both non-invasive and
invasive tumour cells (Figure 3b). MIF levels were way in
excess over the added 150 ng/ml and significantly
increased over the release seen in MCF-12A. The most dra-
matic effect was seen in MDA-MB-468 stimulated with
rMIF for 20 min, where secreted MIF levels reached up to
1000 ng/ml, but also in MDA-MB-231, in which MIF
secretion reached 500 ng/ml. Upregulation of MIF secre-
tion by MIF was specific as boiled rMIF and a control
buffer had no effect (data not shown). Whereas in MDA-
MB-468, secreted MIF peaked at 20 min and then
declined, secretion in MDA-MB-231 exhibited a broad
plateau between 20 min and 48 h of stimulation with
rMIF (Figure 3b). We calculated the relative upregulation
factors of MIF secretion (ratio of rMIF-induced MIF secre-
tion over basal MIF secretion) in both breast cancer cell
types. This analysis demonstrated that the invasive cells
exhibited dramatic relative upregulation factors of up to
55-fold (Figure 3c), whereas relative upregulation in
MDA-MB-468 was less than 10-fold and even lower than
in normal breast epithelial cells. rMIF-triggered secretion
of endogenous breast cancer cell-MIF is likely to encom-
pass both a burst of preformed MIF release at 10–20 min
and de novo synthesized MIF, appearing 4 h after inflam-
matory stimulation with rMIF. Thus, MIF secretion from
breast cancer cells could be strongly influenced by auto- or
paracrine MIF effects in the tumour-stroma microenviron-
ment.
MIF supports the proliferation rate of breast cancer cells
We next compared unstimulated proliferation rates in two
breast cancer cell lines and MCF-12A by BrdU incorpora-
tion assay. Invasive MDA-MB-231 cells showed the high-
est baseline proliferation rate (~7.8-fold), while MDA-
MB-468 proliferated 2.1-fold stronger than MCF-12A cells
(Figure 4a). We then stimulated the cells with different
rMIF concentrations, ranging from 0–150 ng/ml. rMIF
enhanced the proliferation of both tumour cell lines and
also that of MCF-12A (Figure 4b). Peak stimulation was
obtained with 10 ng/ml rMIF, a typical concentration
measured in (patho)physiological fluids [2], but overall,Page 4 of 18
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MIF is overexpressed in breast cancer cells, but differs in its expression between invasive versus non-invasive cellsFigure 1
MIF is overexpressed in breast cancer cells, but differs in its expression between invasive versus non-invasive 
cells. (a) Comparison of MIF mRNA levels in non-tumorous MCF-12A cells with the invasive MDA-MB-231 and non-invasive 
MDA-MB-468 and ZR-75-1 breast cancer cell lines. mRNA of non-stimulated cells was isolated, transcribed to cDNA, and MIF 
gene expression measured by real-time PCR. Gene expression levels are shown relative to the expression level in MCF-12A. 
Data are means of two determinations and are representative of two independent experiments. (b) As in (a) but comparison 
of MIF protein levels by Western blot. Actin was used as a loading control. (c) Quantification of Western blot by densitome-
try, using actin for standardization. The quantification data are means ± SD of 4 independent experiments. P values indicate sta-
tistically significant differences between MIF expression in the breast cancer cell lines compared to MCF-12A.
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The MIF receptor CD74 is overexpressed in invasive MDA-MB-231 cellsFigure 2
The MIF receptor CD74 is overexpressed in invasive MDA-MB-231 cells. (a) Comparison of CD74 expression levels 
between MDA-MB-231, non-invasive MDA-MB-468, and non-tumorous MCF-12A cells by Western blot analysis. Lysates of 
non-stimulated cells were analysed by Western blot and band densitometry analysis against human CD74 and actin. Numbers 
indicate relative CD74/actin ratios. The quantification is representative of three independent experiments. (b) Comparison of 
CD74 expression levels between MDA-MB-231, non-invasive MDA-MB-468, and non-tumorous MCF-12A cells by fluores-
cence microscopy. Surface-expressed CD74 was revealed by FITC-labelled anti-CD 74 Ab. As a negative control, cells were 
labelled with a FITC-labelled secondary anti-mouse antibody. Photographs are representative of two independent experiments.
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MIF secretion from breast cancer cells is upregulated by exogenous MIFFigure 3
MIF secretion from breast cancer cells is upregulated by exogenous MIF. (a) Comparison of MIF secretion levels in 
unstimulated non-invasive MDA-MB-468, invasive MDA-MB-231 tumour cells, and MCF-12A control cells. Supernatants of 
100,000 cells were subjected to human MIF ELISA at the indicated time intervals. Of note, MDA-MB-468 cells secreted MIF lev-
els of up to 35 ng/ml. Asterisks indicate statistical significance compared to MCF-12A. (b) Exogenous rMIF dramatically upreg-
ulates the secretion of MIF from breast cancer cells. As in (a), but stimulation of cells with 150 ng/ml rMIF for the indicated 
time periods. Asterisks indicate statistical significance compared to MCF-12A. (c) Invasive MDA-MB-231 breast cancer cells 
exhibit the highest relative increase in MIF secretion. Relative increase of MIF secretion calculated from (b). To account for the 
addition of the 150 ng/ml exogenously added rMIF, this value was subtracted for all incubations. Data represent means ± SD of 
three determinations and two (b) or three (a and c) independent experiments.
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BMC Cancer 2009, 9:230 http://www.biomedcentral.com/1471-2407/9/230proliferation rates induced by rMIF were moderate (≤ 1.3-
fold). To test for autocrine effects, cells were cultured
under unstimulated conditions and endogenously pro-
duced MIF blocked by neutralizing anti-MIF antibody or
by an antibody against CD74. Both antibodies, but not an
isotype IgG, led to markedly reduced proliferation rates in
MDA-MB-468 and MDA-MB-231 by 50–70%. By contrast,
proliferation of MCF-12A was not affected (Figure 4c).
The remaining proliferation rates of 30–50% imply
engagement of additional MIF signalling pathways such
as the MIF/CXCR4 pathway [5].
In conjunction, these experiments showed that prolifera-
tion of both non-invasive and invasive breast cancer cells
is driven by autocrine MIF action, encompassing the secre-
tion of endogenous MIF and signalling through MIF/
CD74. It is of note that the breast cancer cell type exhibit-
ing the highest overall (surface + endolysosomal) CD74
expression levels (see Figure 2), showed the greatest
response to MIF.
MIF promotes migration and invasion of breast cancer 
cells
MIF has been demonstrated to directly and indirectly act
as a chemoattractant for leukocytes, fibroblasts, and
tumour cells [5,36,37]. To study the pro-invasive activities
of MIF on breast cancer cell migration, MDA-MB-231 cells
were calcein-labelled and subjected to Transwell assays
applying Matrigel-coated filters. MIF significantly and
dose-dependently stimulated the migration/invasion of
MDA-MB-231 (Figure 5; maximum effect at 50 ng/ml
rMIF). Thus, rMIF promotes the migration and invasion of
breast cancer cells through basement membrane-like lay-
ers in a chemokine-like manner, confirming the notion
that MIF produced in the microenvironment surrounding
breast tumour cells may act in a pro-invasive manner.
MIF is overexpressed in breast cancer tissue in vivo
The in vitro studies suggested that exogenous MIF derived
from the tumour microenvironment promotes prolifera-
tion, adhesion, and invasion of CD74+ invasive breast
cancer cells. However, the association between MIF serum
levels or MIF expression within breast cancer tissue and
breast cancer progression in humans has been controver-
sial. We thus performed a comprehensive retrospective
study correlating MIF expression levels with clinical and
pathological markers relevant in breast cancer using a tis-
sue microarray (TMA) with 175 primary invasive breast
cancers and 35 normal breast tissues. For patient charac-
teristics see supplementary table (see Additional File 1).
MIF protein expression was observed in normal breast
epithelial cells (Figure 6a, b) and breast tumour cells (Fig-
ure 6c–e). Although MIF expression was variable in both
normal and malignant breast tissue, abundant MIF
expression was predominantly found in tumour cells.
Overall, we found that MIF levels were upregulated in
breast cancer tissue compared to normal breast epithe-
lium according a semi-quantitative immunoreactivity
score (Remmele and Stegner; Figure 6g).
High MIF expression in breast tumour tissue correlates 
with tumour size and hormone receptor status and is 
associated with favourable survival
Next, we correlated MIF expression levels in primary
human breast cancer with clinicopathological parameters.
Table 1 shows the correlations obtained when high (IRS =
6–12) and low (IRS = 0–4) MIF expression was compared
by descriptive Fisher's exact test with tumour size, lymph
node status [38], histological grade, as well as estrogen
(ER), progesterone (PR), and epidermal growth factor
(EGFR) receptor status. MIF expression was highly signifi-
cantly associated with tumour size (pT) in an inverse
manner (p = 0.007). Thus large tumours (>2 cm) being
associated with poor prognosis predominantly expressed
low levels of MIF (IRS<4). A highly significant positive
correlation was found between abundant MIF expression
MIF augments the proliferation rate of breast cancer cellsFigure 4 (see pr vious page)
MIF augments the proliferation rate of breast cancer cells. (a) Proliferation of unstimulated breast epithelial and 
breast carcinoma cell lines. Proliferation was measured by BrdU assay and is represented as percent of the baseline prolifera-
tion rate of MCF-12A. Proliferation rates of MDA-MB-231 and -468 are markedly and significantly (p values indicated) higher 
than that of MCF-12A. (b) Exogenous rMIF slightly but significantly enhances the proliferation rate of normal breast epithelial 
and breast carcinoma cell lines. As in (a) except that rMIF at indicated concentrations was added to cells for 24 h. Control 
cells (0 ng/ml) received control buffer (final dialysis refolding buffer). Asterisks indicate statistically significant differences com-
pared to the corresponding control incubations: *, p < 0.05; **, p < 0.01. (c) Endogenous MIF supports proliferation of breast 
cancer cells by an autocrine loop and inhibition of proliferation by anti-MIF and anti-CD74 antibodies. Unstimulated prolifera-
tion of breast cancer cells as in (a) was compared to that of MCF-12A in the presence versus absence of neutralising anti-MIF 
and anti-CD74 antibodies. Control cells were incubated with equivalent amounts of PBS and isotype IgG had no effect (data 
not shown). Statistically significant differences (in comparison to cells not treated with antibody) are indicated by asterisks: *, p 
< 0.05; **, p < 0.01. Proliferation rates are means ± SD of two (b) or three (a, c) independent experiments with two (a) or 
three (b, c) determinations.Page 9 of 18
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MIF promotes the migration and invasion of breast cancer cellsFigure 5
MIF promotes the migration and invasion of breast cancer cells. Invasive MDA-MB-231 cells were incubated in the 
upper Matrigel-coated insert of a Transwell chamber and their migration and invasion measured in response to rMIF added as 
a chemoattractant to the lower chamber at indicated concentrations. Invaded Calcein-labelled cells were counted by fluores-
cence microscopy. (a) Quantification of 5 independent experiments taking 10 pictures each. Data points are means ± SD and 
asterisks indicate significant increases of the invasion rate (*, p < 0.05; **, p < 0.01). (b) Representative fluorescence micros-
copy images comparing the effect 50 ng/ml MIF with a control incubation (0 ng/ml MIF).
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MIF is overexpressed in breast cancer tissueFigure 6
MIF is overexpressed in breast cancer tissue. (a-f) Immunohistochemical stainings of MIF protein expression on a tissue 
microarray (TMA) of human breast cancer tissue specimens. Representative stainings applying a MIF antibody are shown. (a, b) 
Normal breast epithelia with moderate MIF protein expression (IRS = 4). (c, d) Invasive breast tumour with strong MIF pro-
tein expression (IRS = 8). (e, f) Samples of invasive mamma carcinoma were used as positive and negative control. For negative 
control, the primary antibody was omitted. Original magnifications: 100× for a, c, e, f; 400× for b, d. (g) Box plot analysis illus-
trating the distribution of MIF protein expression in normal breast tissue and breast cancer tissue. The y axis indicates the IRS 
of cytoplasmic MIF protein staining in normal (n = 35) and breast cancer tissue (n = 175) analysed on the TMA. Median MIF 
expression was found to be increased in human breast tumours (median IRS = 8) compared to normal breast epithelia (median 
IRS = 6). Horizontal lines: group medians; boxes: 25–75% quartiles; vertical lines: range and minimum.
BMC Cancer 2009, 9:230 http://www.biomedcentral.com/1471-2407/9/230and PR status (p = 0.006). In addition, positive correla-
tions with the ER and EGFR status were measured (p =
0.028 and p = 0.038, respectively). Thus surprisingly,
abundant MIF expression in breast tumour tissue corre-
lates with markers associated with a favourable prognosis,
i.e. pT, positive ER and PR status. No correlations were
observed with lymph node status and histological grade.
The obtained correlation between MIF expression in
breast tumour tissue and tumour size and hormone recep-
tor levels tempted us to postulate that MIF overexpression
might be correlated with increased tumour-specific sur-
vival in breast cancer patients. Patients with strong
cytosolic MIF expression in the breast cancer tissue (IRS =
6–12) showed a highly significant increase in overall sur-
vival (OS) compared to the MIF low expresser group with
an IRS = 0–4 (5-year OS = 67% versus 50%, respectively;
p = 0.0019; Figure 7 and Table 2). In line with these find-
ings, 5-year recurrence-free survival (RFS) was 52% in the
MIF high expressers compared to 36% in the low express-
ers (p = 0.0327; Figure 7 and Table 2). IRS analysis of the
PR status paralleled that of MIF with high PR concentra-
tions correlating with increased OS and RFS rates (p <
0.001 and p = 0.01, respectively). Of note, tumour size,
lymph node status, and histological grade positively and
significantly correlated with OS and RFS in our cohort of
breast cancer patients underscoring the suitability of this
cohort to analyse new prognostic marker molecules. Mul-
tivariate Cox regression models including factors possibly
influencing OS/RFS in relation to MIF protein expression
failed to exhibit significance, indicating that MIF is not an
independent prognostic marker in breast cancer, probably
due to its close relation to hormone receptor status (data
not shown).
Discussion
MIF is not only a mediator of acute and chronic inflam-
matory conditions [1], but also plays a role in cancerogen-
esis. MIF overexpression has been observed in several
human tumours and molecular links between MIF and
p53, apoptosis, JAB1/CSN5, and cell cycle regulation
[6,7,18,22,23,39] suggest that MIF is important in regulat-
ing the balance between cell homeostasis and neoplastic
behaviour. Moreover, MIF has angiogenic potential and
Table 1: Clinicopathological parameters in relation to MIF protein expression
MIF protein expression
Variable na IRS (0–4) IRS (6–12) P valued
Tumour sizeb
pT1 48 13 35 0.007
pT2 86 24 62
pT3 12 3 9
pT4 27 16 11
Lymph node statusb
pN0 67 17 50 0.190
pN1-3 100 35 65
Histological grade
G1 19 9 10 0.933
G2 73 18 55
G3 79 29 50
Histological type
invasive ductal 145 51 94 0.496
invasive lobular 13 3 10
other 17 5 12
Estrogen receptor status
negative (IRSc 0–2) 46 21 25 0.028
positive (IRS 3–12) 96 26 70
Progesterone receptor status
negative (IRS 0–2) 101 39 62 0.006
positive (IRS 3–12) 49 8 41
EGFR status
negative (IRS 0) 65 28 37 0.038
positive (IRS 1–3) 92 25 67
a Only female patients with primary, unilateral, invasive breast cancer were included. Significant p values are marked in bold face. b According to the 
TNM classification of Sobin and Wittekind [38]. c IRS = immunoreactive score according to Remmele and Stegner [35]. d Fisher's exact test. 
Significant p values are marked in bold face.Page 12 of 18
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High MIF expression in breast tumour tissue positively correlates with survivalFi ure 7
High MIF expression in breast tumour tissue positively correlates with survival. Kaplan-Meier analyses of overall 
survival (OS) (a) and recurrence-free survival (RFS) (b) in relation to MIFprotein expression in breast cancer tissue specimens 
of 174 and 165 patients, respectively. Distribution of time (months)- and tumour-related death among 174 breast cancer 
patients with abundant (upper graph) or low (lower graph) MIF expression is shown. (a) Patients featuring low MIF protein 
expression (IRS = 0–4) have a reduced estimated mean five-year OS survival rate of 50% compared to 67% survival probability 
for patients with strong MIF expression (IRS = 6–12). (b) Patients exhibiting low MIF protein expression (IRS = 0–4) have an 
increased risk for tumour relapse (mean RFS rate of 52%) after five years compared to 36% for patients with strong MIF 
expression (IRS = 6–12).
a
b
BMC Cancer 2009, 9:230 http://www.biomedcentral.com/1471-2407/9/230enhances the expression of proangiogenic CXCL8 and vas-
cular endothelial growth factor (VEGF) [37,40]. Interest-
ingly, MIF exhibits similarities with CXCL8 and shares
with this chemokine an ELR-like motif [41]. In fact, MIF
acts as a non-cognate ligand of CXCR2 and drives leuko-
cyte recruitment through CXCR2 [5]. Thus, MIF is a
cytokine/chemokine and autocrine/paracrine growth fac-
tor promoting tumourigenesis.
Only a few studies have addressed the role of MIF in breast
cancer. Bando and colleagues noticed MIF overexpression
in 93 primary breast cancer tissues with MIF localizing to
tumour as well as stromal cells including TAMs [12]. Of
note, in that cohort intra-tumoural MIF levels and circu-
lating MIF inversely correlated with nodal status. Intra-
tumoural MIF levels correlated with proinflammatory
macrophage cytokines, suggesting that MIF regulates and
is regulated by tumour-stroma interactions, particularly in
cancers with minimal nodal spread [12]. While the over-
expression of MIF in primary human breast cancer tissue
was recently confirmed [31], analysis of that cohort (85
patients with MIF-positive and 36 patients with MIF-neg-
ative tumours) revealed that positive MIF expression was
associated with unfavourable disease-free, but not overall,
survival. This latter study also demonstrated that MIF lev-
els in breast tumour tissue correlated with tumour CXCL8
levels, whereas no correlations with steroid hormone
receptor status were observed [31]. Thus, while there is
consensus from these reports that MIF is overexpressed in
human breast cancer, its functional correlation with
breast tumourigenesis has remained unclear. In own prior
work leading up to the current investigation, we observed
strong MIF expression in MCF-7 and ZR-75-1 breast can-
cer cells, and blockade of MIF secreted from these cells
suggested a causal role of extracellular MIF in breast can-
cer cell survival involving the AKT/PI3K pathway [21].
These findings are in favour of a pro-tumourigenic role of
MIF. Similarly, Hagemann et al. demonstrated that MIF
enhanced MCF-7 invasiveness and matrix metalloprotein-
ase-9 (MMP-9) activity. When coculturing MCF-7 cells
with human macrophages, MIF was identified as a prom-
inent target in tumour cells that was upregulated upon
inflammatory cytokine production by cocultured macro-
phages. In turn, induced tumour cell-derived MIF was crit-
Table 2: Univariate analysis of clinicopathological parameters influencing recurrence-free survival (RFS) and overall survival (OS).
Variable RFS OS
na events p valued n events p value
Clinicopathological factors:
Tumour sizeb
pT1 46 10 48 8
pT2 83 39 86 30
pT3 11 5 < 0.001 12 3 0.001
pT4 24 16 27 18
Lymph node statusb
pN0 66 14 68 11
pN1-3 97 53 < 0.001 101 44 < 0.001
Histological grade
G1 18 4 19 5
G2 69 23 74 18
G3 78 43 < 0.001 80 37 0.003
Histological type
invasive ductal 138 63 142 50
invasive lobular 12 3 14 5
other 15 4 0.167 17 5 0.876
Estrogen receptor status
negative (IRSc 0–2) 46 24 46 19
positive (IRS 3–12) 93 32 0.065 98 28 0.076
Progesterone receptor status
negative (IRSc 0–2) 95 48 102 44
positive (IRS 3–12) 50 13 0.010 50 8 < 0.001
MIF protein expression
weak (IRSc 0–4) 51 26 57 27
strong (IRS 5–12) 114 44 0.033 117 32 0.002
EGFR status
negative (IRSc 0) 59 21 65 23
positive (IRS 1–3) 91 44 0.146 93 35 0.867
a Only female patients with primary, unilateral, invasive breast cancer were included. b According to the TNM classification of Sobin and Wittekind 
[38]. c IRS = immunoreactive score according to Remmele and Stegner [35]. d Fisher's exact test. Significant p values are marked in bold face.Page 14 of 18
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by macrophages [32]. In conjunction, these prior and in
part conflicting studies indicate that despite its established
overexpression in breast cancer, the contribution of MIF
to breast cancerogenesis is likely to be complex and may
vary between disease stages. The precise function of MIF
may depend on its cellular expression (intracellular, extra-
cellular, breast or stromal cell-derived).
To address these possibilities and to comprehensively
explore MIF's role in breast cancerogenesis, we correlated
MIF expression levels with clinicopathological data in a
large cohort of patients with invasive breast cancer and
studied the effect of MIF on the behaviour of breast cancer
cell lines in vitro. While we confirmed that MIF was mark-
edly overexpressed in non-invasive MDA-MB-468 and ZR-
75-1 breast cancer cells, compared to benign MCF-12A
breast cells, the highly invasive MDA-MB-231 cancer cells
surprisingly showed low MIF expression levels. In con-
trast, expression of the MIF receptor CD74 was elevated in
MDA-MB-231. This suggested that invasive breast cancer
cells are target cells of MIF in breast cancer. Indeed, exog-
enous MIF stimulated MDA-MB-231 proliferation, and
blockade of CD74 blocked MDA-MB-231 proliferation
induced by autocrine MIF activity. However, enhanced
CD74-dependent tumour cell proliferation by autocrine
MIF was also measured in MDA-MB-468 cells. These cells
also expressed some surface CD74, an observation that
explained their responsiveness, but contained markedly
reduced levels of total cellular CD74. Only a small portion
of CD74 is presented at the cell surface at any given time
point, whereas the majority is localized in the endolyso-
somal compartment. It will be of interest to study,
whether signalling from MIF/CD74 complexes originates
from the cell surface or is activated from signalling endo-
somes. In line with our results, secretion of MIF by
tumour cells and autocrine stimulation of neoplastic
behaviour by MIF has previously been observed for sev-
eral tumour cell types [14,32,42].
MIF is expressed in numerous cell types including tumour
cells. Preformed MIF protein resides in the cytosol, from
where it is secreted by a non-conventional pathway upon
stimulation. Stimuli such as endotoxin, inflammatory
cytokines, or oxidized lipids have all been demonstrated
to be potent triggers of MIF secretion [1,43]. Autocrine
MIF activation loops have been implicated in tumour cell
growth. Here we tested whether exogenous MIF would
induce MIF secretion. Both MDA-MB-231 and MDA-MB-
468 breast cancer cells slowly secreted MIF during unstim-
ulated cultivation. Unspecific cell death could be excluded
(data not shown). Stimulation of cells rMIF led to a dra-
matic upregulation of the secretion rate of endogenous
MIF of up to 500–1000 ng/ml in MDA-MB-468 and MDA-
MB-231. Peak secretion occurred after 20 min, indicating
that exogenous MIF triggered massive release of pre-
formed MIF stores. Relative upregulation rates over back-
ground secretion and added rMIF were even more
striking. MIF secretion in invasive MDA-MB-231 cells
increased 28-fold after 10 min and reached a sustained
rate of 50-fold thereafter. It is worthwhile of mentioning
that the concentration of rMIF found to trigger optimal
release of endogenous MIF was 150 ng/ml. Although this
rMIF concentration is well within the range of MIF con-
centrations measured and known in pathophysiologic
conditions to promote inflammation and pro-tumouri-
genic behaviour, it is currently mechanistically unclear
why lower concentrations of rMIF (10–50 ng/ml) sufficed
to lead to an enhancement of breast cancer cell prolifera-
tion and invasion. Thus, invasive breast cancer cells exhib-
iting low MIF expression and secretion levels at baseline
are capable of dramatically upregulating MIF upon short
term triggering with exogenous MIF, possibly derived
from tumour/stroma interactions.
We found that anti-MIF and anti-CD74 antibodies
potently blocked breast cancer cell proliferation induced
by autocrine or exogenous MIF. Thus, as observed in pros-
tate and gastric cancer [25,26], MIF/CD74 interactions
appear to play a role in breast tumourigenesis. It is inter-
esting to note, that upon MIF binding CD74 associates
with CD44 and signalling induced by MIF/CD74/CD44
has been implicated in increased B cell survival [28]. The
role of the various known CD44 variants in breast cancer
is a matter of debate [29]. Recent reports indicate that
CD44 overexpression could to be associated with an
increased disease-free survival of patients suffering from
node-negative invasive breast carcinomas [30,44]. How-
ever, numerous other studies have suggested that CD44
promotes invasiveness of breast cancer cells [45-47]. Thus,
future studies should address the role of CD74/CD44
complexes in MDA-MB-231 invasion.
In conjunction with the study by Hagemann et al., it may
be speculated that in human breast cancer tissue, TAM-
derived MIF triggers breast cancer cell activation. In fact,
the assumption that MIF promotes breast tumour cell
invasiveness was underscored by Matrigel invasion assays
using MDA-MB-231. The transmigration rate of these cells
through Matrigel was markedly enhanced when rMIF was
added to the lower chamber, in line with recent observa-
tions demonstrating that MIF functions as a chemoattract-
ant [5,48]. Furthermore, the tremendous increase in the
rate of MIF secretion as observed in breast cancer cells fol-
lowing stimulation with rMIF suggests that TAM-derived
MIF could trigger MIF secretion from breast cancer cells,
thus igniting a local MIF amplification loop. In turn, as
manifest from the study of Hagemann [32], breast cancer
cell-derived MIF might then modulate (pro-invasive)
TAM activities as well as induce a broad range of inflam-Page 15 of 18
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secondary mediators that may further promote tumouri-
genesis [14,22].
As MIF is expressed in breast cancer cell lines, promotes
breast tumour cell proliferation and invasion, and con-
tributes to stroma/tumour interactions, one may expect
that MIF is overexpressed in breast cancer in vivo and
would correlate with a poor survival prognosis and mark-
ers such as EGFR or HER2 [49].
We compared intra-tumoural MIF levels in specimens
from 175 breast cancer patients with those of 35 normal
breast tissues. Confirming earlier studies by Bando et al.
[12] and Xu and colleagues [31], we found that MIF pro-
tein was significantly upregulated in breast cancer tissues
compared to normal breast epithelium. However, there
are differences between our study and the two previous
investigations. We detected substantial but varying con-
centrations of MIF protein in essentially all tumour cells,
where MIF was primarily localised in the cytosol. In con-
trast, Bando and colleagues in their cohort of 93 primary
cancer tissues predominantly observed nuclear MIF stain-
ing. In the cohort studied by Xu et al., surprisingly only 1/
3 of the patients (n = 36) had MIF-positive breast cancer
tissues. Xu et al. used a polyclonal anti-MIF antibody,
whereas in our study the highly specific anti-MIF MAB
289 was applied.
At first sight, our in vitro data are in contrast to the corre-
lations observed in vivo. We noticed a significant positive
correlation between MIF levels and hormone receptors
(especially PR) and a significant negative correlation
between MIF and tumour size. PR and ER are markers of a
favourable prognosis in breast cancer and characterize
specific subtypes of the disease. Xu et al. did not detect any
correlation between MIF and ER or PR in their cohort, but
picked up a positive correlation with EGFR, with which we
also see a moderately significant correlation (p = 0.038).
Bando et al. only measured ER and found no correlation
with MIF. Despite these differences that may in part be
due to the different cohorts studied, the link between MIF
levels and ER/PR status as observed in our cohort is of
interest, because these parameters may be molecularly
connected to MIF through JAB1/CSN5, which is abun-
dantly expressed in breast cancer [50]. JAB1 is an intracel-
lular binding partner of MIF [7] and has been
demonstrated to interact with ER and PR [51].
All three studies concur in failing to see any correlations
between breast cancer MIF expression levels and tumour
size or histological tumour grades [12,31]. Interestingly,
Bando et al. noticed that MIF levels in breast tumour tissue
were inversely correlated with nodal status. However, no
such correlation was detected in our study and in the
study by Xu et al.. The observation that abundant MIF
expression is significantly associated with breast tumours
of small size supports the notion that intracellular MIF
can inhibit tumour cell proliferation. This hypothesis is
underscored by the finding that breast cancer patients
with abundant MIF expression have a favourable progno-
sis both according to tumour-specific OS and RFS. The
strong statistical significance of these data suggests that
high levels of MIF expressed in the cytosol of breast carci-
noma cells are beneficial for the outcome of breast cancer.
Thus, there appears to be a dichotomy of MIF functions in
breast cancer progression. We speculate that intracellular
MIF in the breast cells has a protective function, whereas
extracellular MIF, be it TAM-derived or produced by carci-
noma cells upon stroma/tumour interactions, is patho-
genic. The anti-tumour effect of cytosolic breast epithelial
MIF might be mediated through JAB1/CSN5 which pro-
motes p27 degradation [52] and is counter-regulated by
MIF [7] or could reflect cell homeostatic activities of MIF
[23,53]. Pro-tumourigenic effects of extracellular MIF
have been reported [31,32] and could be due to MMP acti-
vation, or MIF's pro-angiogenic and inflammatory activ-
ity. In fact, it was suggested that MIF is a determinant of
the M1-subtype of TAMs and that mammary adenocarci-
noma cells lead to MIF ablation in M1-TAMs, inducing a
switch towards M2 polarization [54].
Conclusion
This study in conjunction with prior observations by oth-
ers indicates that MIF has a dual role in breast cancer.
Intracellular MIF localised to breast cancer cells may be
indicative of a favourable prognosis, whereas extracellular
breast tumour tissue-derived MIF could be proinflamma-
tory and will likely constitute an unfavourable prognosis
marker.
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